In-silico Prediction of Binding Affinities and Pharmacokinetic Parameters of Indoline-2-one Derivatives as Anticancer HDAC Inhibitors
DOI:
https://doi.org/10.32947/ajps.v26i1.1367Keywords:
Anticancer HDAC1 inhibitors, Indoline-2-one derivatives, In-silico study, Molecular docking, PLP fitness, Pharmacokinetic Parameters, SwissADMEAbstract
The present work explores the molecular docking and pharmacokinetic features of indoline-2-one derivatives as potential anticancer agents by targeting histone deacetylase enzyme (HDAC1) which is the crucial element in tumor progression. Docking studies on the derivatives were performed based on histone deacetylase enzyme crystal structure (PDB ID: 1C3S) comparing with reference inhibitor vorinostat to ascertain inhibitory activity. Docking outcomes demonstrated that the fitness scores of all analogs are superior to those of vorinostat. The binding types were stabilized mainly by hydrogen bond, hydrophobic contact and coordination with the zinc ion in the active site of enzyme, showing good complementarity and certain inhibitory effect. Pharmacokinetics screening via the Swiss ADME (absorption, distribution, metabolism, and excretion) platform revealed that these compounds complied with the Lipinski’s rule for drug likeness, and had favorable physicochemical properties (good lipophilicity, suitable topological polar surface area values as well as good gastrointestinal absorption). The indoline-2-one derivatives did not interact with P-glycoprotein and presented a good oral bioavailability.
These results indicate that these compounds exhibit predicted inhibitory potential toward the histone deacetylase enzyme, supported by favorable docking scores and pharmacokinetic properties and can be further optimized for anticancer drug research.
References
1- Sriharikrishnaa S, Suresh PS, Prasada K S. An introduction to fundamentals of cancer biology. Optical Polarimetric modalities for biomedical research: Springer; 2023. p. 307-30.
2- Jamasbi E, Hamelian M, Hossain MA, Varmira K. The cell cycle, cancer development and therapy. Molecular biology reports. 2022;49(11):10875-83.
3- Kontomanolis EN, Koutras A, Syllaios A, Schizas D, Mastoraki A, Garmpis N, et al. Role of oncogenes and tumor-suppressor genes in carcinogenesis: a review. Anticancer research. 2020;40(11):6009-15.
4- De Marco K, Sanese P, Simone C, Grossi V. Histone and DNA methylation as epigenetic regulators of DNA damage repair in gastric cancer and emerging therapeutic opportunities. Cancers. 2023;15(20):4976.
5- Alam J, Huda MN, Tackett AJ, Miah S. Oncogenic signaling-mediated regulation of chromatin during tumorigenesis. Cancer and Metastasis Reviews. 2023;42(2):409-25.
6- Alwan SM, Ali R, ben Sulaiman İAI. In Silico Profiling of Histone Deacetylase 8 Inhibitory Activity: A Computational Analysis of Novel Dipeptide-Based Compounds Cross-Linked with Hydroxamic Acid. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2024;24(2):178-89.
7- Kang H, Kim B. Bioactive compounds as inhibitors of inflammation, oxidative stress and metabolic dysfunctions via regulation of cellular redox balance and histone acetylation state. Foods. 2023;12(5):925.
8- Halasa M, Adamczuk K, Adamczuk G, Afshan S, Stepulak A, Cybulski M, et al. Deacetylation of transcription factors in carcinogenesis. International Journal of Molecular Sciences. 2021;22(21):11810.
9- Wang C, Ma X. The role of acetylation and deacetylation in cancer metabolism. Clinical and Translational Medicine. 2025;15(1):e70145.
10- Han H, Feng X, He T, Wu Y, He T, Yue Z, et al. Discussion on structure classification and regulation function of histone deacetylase and their inhibitor. Chemical Biology & Drug Design. 2024;103(1):e14366.
11- Dai Y, Wei T, Shen Z, Bei Y, Lin H, Dai H. Classical HDACs in the regulation of neuroinflammation. Neurochemistry international. 2021;150:105182.
12- Teixeira CS, Cerqueira NM, Gomes P, Sousa SF. A molecular perspective on sirtuin activity. International Journal of Molecular Sciences. 2020;21(22):8609.
13- Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, et al. Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability. Genes. 2020;11(5):556.
14- Chen C, Wei M, Wang C, Sun D, Liu P, Zhong X, et al. The histone deacetylase HDAC1 activates HIF1α/VEGFA signal pathway in colorectal cancer. Gene. 2020;754:144851.
15- Liu T, Wan Y, Xiao Y, Xia C, Duan G. Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy. Journal of medicinal chemistry. 2020;63(17):8977-9002.
16- Jenke R, Reßing N, Hansen FK, Aigner A, Büch T. Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives. Cancers. 2021;13(4):634.
17- Cappellacci L, Perinelli DR, Maggi F, Grifantini M, Petrelli R. Recent progress in histone deacetylase inhibitors as anticancer agents. Current medicinal chemistry. 2020;27(15):2449-93.
18- Raucci A, Zwergel C, Valente S, Mai A. Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic Potential. Journal of Medicinal Chemistry. 2025;68(14):14171-94.
19- Qadir T, Amin A, Sharma PK, Jeelani I, Abe H. A review on medicinally important heterocyclic compounds. The Open Medicinal Chemistry Journal. 2022;16(1).
20- Gandhi PV, Burande SR, Charde MS, Chakole RD. A review on isatin and its derivatives: synthesis, reactions and applications. Journal of Advanced Scientific Research. 2021;12(04):1-11.
21- Baranwal J, Kushwaha S, Singh S, Jyoti A. A review on the synthesis and pharmacological activity of heterocyclic compounds. Current Physical Chemistry. 2023;13(1):2-19.
22- Tumosienė I, Jonuškienė I, Kantminienė K, Mickevičius V, Petrikaitė V. Novel N-substituted amino acid hydrazone-isatin derivatives: Synthesis, antioxidant activity, and anticancer activity in 2D and 3D models in vitro. International journal of molecular sciences. 2021;22(15):7799.
23- Ferraz de Paiva RE, Vieira EG, Rodrigues da Silva D, Wegermann CA, Costa Ferreira AM. Anticancer compounds based on isatin-derivatives: Strategies to ameliorate selectivity and efficiency. Frontiers in molecular biosciences. 2021;7:627272.
24- Al-Khuzaie MG, Fahad MM, Al-Safi AJ. Synthesis, reaction and biological importance of isatin derivatives. Biomedicine and Chemical Sciences. 2022;1(3):193-206.
25- Chowdhary S, Shalini, Arora A, Kumar V. A mini review on isatin, an anticancer scaffold with potential activities against neglected tropical diseases (NTDs). Pharmaceuticals. 2022;15(5):536.
26- Dube ZF, Soremekun OS, Ntombela T, Alahmdi MI, Abo-Dya NE, Sidhom PA, et al. Inherent efficacies of pyrazole-based derivatives for cancer therapy: The interface between experiment and in silico. Future Medicinal Chemistry. 2023;15(18):1719-38.
27- Khan AK, Hamdi MD, Mehde AA. Drug Design, In Silico-Profiling of New Pyrrole Derivatives: Promising Anticancer Agents Against Acute Myeloid Leukemia. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2024;24(3):252-63.
28- Khan AK, Mahmood NR, Sahib MA. Design, In Silico, and Experimental Evaluation of Novel Naproxen–Azetidinone Hybrids as Selective COX-2 Inhibitors. Molecules. 2025;30(22):4358.
29- Mohammed NM. Docking Study, Synthesis, Characterization and Preliminary Cytotoxic Evaluation of new 1, 2, 3, 4-Tetrahydroppyrimidine Derivatives. J Contemp Med Sci| Vol. 2022;8(5):329-36.
30- Attia AJ, Ali KF. Design, Molecular Docking, and Pharmacokinetic Evaluation of Thioimidazole-4-one Derivatives for Asthma Treatment. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2025;25(4):648-62.
31- Drakontaeidi A, Pontiki E. A review on molecular docking on HDAC isoforms: Novel tool for designing selective inhibitors. Pharmaceuticals. 2023;16(12):1639.
32- Sixto-López Y, Bello M, Correa-Basurto J. Insights into structural features of HDAC1 and its selectivity inhibition elucidated by Molecular dynamic simulation and Molecular Docking. Journal of Biomolecular Structure and Dynamics. 2019;37(3):584-610.
33- Khare S, Chatterjee T, Gupta S, Ashish P. Bioavailability predictions, pharmacokinetics and drug-likeness of bioactive compounds from Andrographis paniculata using Swiss ADME. MGM Journal of Medical Sciences. 2023;10(4):651-9.
34- Bülbül EF. Structure-based design of inhibitors of the zinc-dependent enzymes histone deacetylase (HDAC) and UDP-3-O-(R-3-hydroxymyristoylyl)-N-acetylglucosamine deacetylase (LpxC): Dissertation, Halle (Saale), Martin-Luther-Universität Halle-Wittenberg, 2023; 2023.
35- Tran JU, Brown BL. Structural basis for allostery in PLP-dependent enzymes. Frontiers in Molecular Biosciences. 2022;9:884281.
36- Al-Ogaili NA, Mohammed NM. In silico Study of the Inhibitory Effects of Sanguinarine and its Proposed Derivative on Phosphoinositide 3-kinase (PI3K) Isoforms. Tropical Journal of Natural Product Research. 2025;9(10).
37- Haritha M, Sreerag M, Suresh CH. Quantifying the hydrogen-bond propensity of drugs and its relationship with Lipinski's rule of five. New Journal of Chemistry. 2024;48(11):4896-908.
38- Daina A, Zoete V. A boiled‐egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem. 2016;11(11):1117-21.
39- Kar S, Leszczynski J. Open access in silico tools to predict the ADMET profiling of drug candidates. Expert opinion on drug discovery. 2020;15(12):1473-87.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Farah Abdulhaleem Kadhim, Monther Faisal Mahdi, Talal Aburjai, Ayad M.R. Raauf
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
